NASDAQ:AMEDAmedisys Stock Price, Forecast & News

Amedisys' stock was trading at $170.47 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AMED shares have increased by 10.9% and is now trading at $189.07. View which stocks have been most impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amedisys.

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Amedisys.

Amedisys Inc (NASDAQ:AMED) posted its earnings results on Wednesday, May, 6th. The health services provider reported $1.05 EPS for the quarter, topping the Zacks' consensus estimate of $0.97 by $0.08. The health services provider had revenue of $491.70 million for the quarter, compared to analysts' expectations of $507.45 million. Amedisys had a net margin of 6.43% and a return on equity of 23.09%. Amedisys's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $1.11 earnings per share. View Amedisys' earnings history.

14 brokerages have issued 12 month target prices for Amedisys' shares. Their forecasts range from $125.00 to $240.00. On average, they expect Amedisys' share price to reach $191.07 in the next twelve months. This suggests a possible upside of 1.1% from the stock's current price. View analysts' price targets for Amedisys.

News stories about AMED stock have been trending somewhat positive this week, according to InfoTrie. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amedisys earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave media coverage about the health services provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutAmedisys.

Amedisys saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 1,110,000 shares, a drop of 8.3% from the April 30th total of 1,210,000 shares. Based on an average daily volume of 314,000 shares, the days-to-cover ratio is presently 3.5 days. Currently, 3.5% of the company's shares are short sold. View Amedisys' Current Options Chain.

Some companies that are related to Amedisys include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), R1 RCM (RCM), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include Alibaba Group (BABA), NVIDIA (NVDA), Adobe (ADBE), Cisco Systems (CSCO), Netflix (NFLX), CVS Health (CVS), Intel (INTC), Micron Technology (MU), Pfizer (PFE) and Vertex Pharmaceuticals (VRTX).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.85%), Wellington Management Group LLP (4.86%), State Street Corp (3.14%), William Blair Investment Management LLC (3.00%), JPMorgan Chase & Co. (2.72%) and Riverbridge Partners LLC (2.05%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Kkr Credit Advisors (Us) Llc, Linda J Hall, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps. View institutional ownership trends for Amedisys.

AMED stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Eaton Vance Management, William Blair Investment Management LLC, Principal Financial Group Inc., Quantitative Investment Management LLC, Rothschild & Co. Asset Management US Inc., Loomis Sayles & Co. L P, and Morgan Stanley. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, and Sharon Brunecz. View insider buying and selling activity for Amedisys.

AMED stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., AXA, Federated Hermes Inc., APG Asset Management N.V., APG Asset Management N.V., APG Asset Management N.V., Two Sigma Advisers LP, and Invesco Ltd.. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps. View insider buying and selling activity for Amedisys.

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMED stock can currently be purchased for approximately $189.07.

Amedisys has a market capitalization of $6.12 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe.

The official website for Amedisys is www.amedisys.com.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]